Bermary Garrido

Mrs. Bermary Garrido

Endocrine and Metabolic Diseases Research Center. School of Medicine. University of Zulia, Maracaibo
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Carla NavarroCarla Navarro
Carla Navarro
AOAngel Ortega
Angel Ortega
Raquel Gabriela SantelizRaquel Gabriela Santeliz
Raquel Gabriela Santeliz
Bermary GarridoBermary Garrido
Bermary Garrido
MCMaricarmen Chacin
Maricarmen Chacin
VBValmore Bermudez
Valmore Bermudez
The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer.

Verified
Journal Article
Open access
PDF file
RCRaquel Cano
Raquel Cano
VBValmore Bermudez
Valmore Bermudez
NPNestor Andres Galban Perez
Nestor Andres Galban Perez
Bermary GarridoBermary Garrido
Bermary Garrido
Raquel Gabriela SantelizRaquel Gabriela Santeliz
Raquel Gabriela Santeliz
LALissé Angarita
Lissé Angarita
The intricate interplay between the gut microbiota and polyphenols has emerged as a captivating frontier in understanding and potentially harnessing the therapeutic potential of these bioactive compounds. Phenolic compounds, renowned for their antioxidant, anti-inflammatory, antidiabetic, and anticancer properties, are subject to intricate transformations within the gut milieu, where the diverse microbial ecosystem exerts profound effects on their metabolism and bioavailability. Conversely, polyphenols exhibit a remarkable capacity to modulate the composition and activity of the gut microbiota, fostering a bidirectional relationship that extends beyond mere nutrient processing. This symbiotic interaction holds significant implications for human health, particularly in cardiometabolic diseases such as diabetes mellitus, metabolic-dysfunction-associated steatotic liver disease, and cardiovascular disease. Through a comprehensive exploration of molecular interactions, this narrative review elucidates the reciprocal dynamics between the gut microbiota and polyphenols, unveiling novel avenues for therapeutic intervention in cardiometabolic disorders. By unravelling the intricate cross-talk between these two entities, this review underscores the multifaceted roles of polyphenols in overall health and the pivotal role of gut microbiota modulation as a promising therapeutic strategy in mitigating the burden of cardiometabolic diseases.

Verified
Journal Article
Open access
PDF file
MCMervin Chávez-Castillo
Mervin Chávez-Castillo
AOAngel Ortega
Angel Ortega
Lorena Cudris-TorresLorena Cudris-Torres
Lorena Cudris-Torres
PDPablo Duran
Pablo Duran
MRMilagros Rojas
Milagros Rojas
VBValmore Bermudez
Valmore Bermudez
Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.

12 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JSJuan Salazar
Juan Salazar
AOAngel Ortega
Angel Ortega
JPJose Perez
Jose Perez
Bermary GarridoBermary Garrido
Bermary Garrido
Raquel Gabriela SantelizRaquel Gabriela Santeliz
Raquel Gabriela Santeliz
MCMaricarmen Chacin
Maricarmen Chacin
Although not frequently lethal, dermatological diseases represent a common cause of consultation worldwide. Due to the natural and non-invasive approach of phytotherapy, research for novel alternatives, such as polyphenols, to treat skin disorders is a subject of interest in modern medicine. Polyphenols, in particular, have been considered because of their anti-inflammatory, antitumoral, antimicrobial, and antioxidant properties, low molecular weight, and lipophilic nature that enables the passage of these compounds through the skin barrier. This review discusses the treatment of common dermatological diseases such as acne vulgaris, fungal infections, dermatitis, alopecia, and skin cancer, using polyphenols as therapeutic and prophylactic options. The specific molecules considered for each disorder, mechanisms of action, current clinical trials, and proposed applications are also reviewed.

19 May 2025 in Molecules
Verified
Journal Article
Open access
PDF file
AOAngel Ortega
Angel Ortega
PDPablo Duran
Pablo Duran
Bermary GarridoBermary Garrido
Bermary Garrido
AMalexander manzano
alexander manzano
CNCarolina Navarro
Carolina Navarro
VBValmore Bermudez
Valmore Bermudez
Inflammatory lung diseases (ILDs) represent a global public health crisis characterized by escalating prevalence, significant morbidity, and substantial mortality. In response to the complex immunopathogenic mechanisms driving these conditions, novel pharmacological strategies targeting resolution pathways have emerged throughout the discovery of specialized pro-resolving lipid mediator (SPM; resolvins, maresins, and protectins) dysregulation across the ILD spectra, positioning these endogenous molecules as promising therapeutic candidates for modulating maladaptive inflammation and promoting tissue repair. Over the past decade, this paradigm has catalyzed extensive translational research into SPM-based interventions as precision therapeutics for respiratory inflammation. In asthma, they reduce mucus hypersecretion, bronchial hyperreactivity, and airway inflammation, with prenatal SPM exposure potentially lowering offspring disease risk. In COPD, SPMs attenuate amyloid A-driven inflammation, normalizing cytokine/chemokine imbalances and oxidative stress and mitigating COVID-19-associated cytokine storm, enhancing survival. This review synthesizes SPMs’ pharmacotherapeutic mechanisms in ILDs and evaluates current preclinical and clinical evidence.

18 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJuan Salazar
Juan Salazar
PDPablo Duran
Pablo Duran
Bermary GarridoBermary Garrido
Bermary Garrido
HPHeliana Parra Pelosi
Heliana Parra Pelosi
Marlon HernándezMarlon Hernández
Marlon Hernández
VBValmore Bermudez
Valmore Bermudez
Patients undergoing metabolic surgery have factors ranging from anatomo-surgical, endocrine metabolic, eating patterns and physical activity, mental health and psychological factors. Some of the latter can explain the possible pathophysiological neuroendocrine, metabolic, and adaptive mechanisms that cause the high prevalence of weight regain in postbariatric patients. Even metabolic surgery has proven to be effective in reducing excess weight in patients with obesity; some of them regain weight after this intervention. In this vein, several studies have been conducted to search factors and mechanisms involved in weight regain, to stablish strategies to manage this complication by combining metabolic surgery with either lifestyle changes, behavioral therapies, pharmacotherapy, endoscopic interventions, or finally, surgical revision. The aim of this revision is to describe certain aspects and mechanisms behind weight regain after metabolic surgery, along with preventive and therapeutic strategies for this complication.